SIRT2 is a tumor suppressor that connects aging, acetylome, cell cycle signaling, and carcinogenesis

Translational Cancer Research

Volumn 1, Issue 1, 2012, Pages 15-21

  Park, Seong Hoon ^a   Zhu, Yuming ^a   Ozden, Ozkan ^a   Kim, Hyun Seok ^c   Jiang, Haiyan ^a   Deng, Chu Xia ^d   Gius, David ^a,b   Vassilopoulos, Athanassios ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Ewha Womans University   (South Korea)

^d NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

Acetylation; APC C complex; Cancer; Mitosis; Sirt2; Sirtuins

Indexed keywords

APC PROTEIN; SIRTUIN 2;

ACETYLATION; AGING; CAENORHABDITIS ELEGANS; CARCINOGENESIS; CELL CYCLE; GENE FUNCTION; GENOMIC INSTABILITY; HUMAN; MITOSIS; NONHUMAN; REVIEW; SACCHAROMYCES CEREVISIAE; SEX DIFFERENCE; TUMOR SUPPRESSOR GENE;

EID: 84962778960     PISSN: 2218676X     EISSN: 22196803     Source Type: Journal    
DOI: 10.3978/j.issn.2218-676X.2012.05.01     Document Type: Review

References (56)

1. Bishop JM. Viral oncogenes. Cell 1985;42:23-38.
2. Gius D, Cui H, Bradbury CM, et al. Distinct effects on gene expression of chemical and genetic manipulation of the cancer epigenome revealed by a multimodality approach. Cancer Cell 2004;6:361-71.
3. Sherr CJ, McCormick F. The RB and p53 pathways in cancer. Cancer Cell 2002;2:103-12.
4. Hunter T. Oncoprotein networks. Cell 1997;88:333-46.
5. Knudson AG Jr. Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci USA 1971;68:820-3.
6. Deng CX. BRCA1: cell cycle checkpoint, genetic instability, DNA damage response and cancer evolution. Nucleic Acids Res 2006;34:1416-26.
7. Land H, Parada LF, Weinberg RA. Tumorigenic conversion of primary embryo fibroblasts requires at least two cooperating oncogenes. Nature 1983;304:596-602.
8. Feinberg AP, Johnson LA, Law DJ, et al. Multiple tumor suppressor genes in multistep carcinogenesis. Tohoku J Exp Med 1992;168:149-52.
9. Land H, Chen AC, Morgenstern JP, et al. Behavior of myc and ras oncogenes in transformation of rat embryo fibroblasts. Mol Cell Biol 1986;6:1917-25.
10. Sherr CJ. Principles of tumor suppression. Cell 2004;116:235-46.
11. Ershler WB, Longo DL. The biology of aging: the current research agenda. Cancer 1997;80:1284-93.
12. Longo VD, Kennedy BK. Sirtuins in aging and age-related disease. Cell 2006;126:257-68.
13. Kim EJ, Kho JH, Kang MR, et al. Active regulator of SIRT1 cooperates with SIRT1 and facilitates suppression of p53 activity. Mol Cell 2007;28:277-90.
14. Wood JG, Rogina B, Lavu S, et al. Sirtuin activators mimic caloric restriction and delay ageing in metazoans. Nature 2004;430:686-9.
15. Vassilopoulos A, Fritz KS, Petersen DR, et al. The human sirtuin family: evolutionary divergences and functions. Hum Genomics 2011;5:485-96.
16. Hallows WC, Albaugh BN, Denu JM. Where in the cell is SIRT3?-functional localization of an NAD+-dependent protein deacetylase. Biochem J 2008;411:e11-e13.
17. Yang XJ, Seto E. Lysine acetylation: codified crosstalk with other posttranslational modifications. Mol Cell 2008;31:449-61.
18. Schwer B, Bunkenborg J, Verdin RO, et al. Reversible lysine acetylation controls the activity of the mitochondrial enzyme acetyl-CoA synthetase 2. Proc Natl Acad Sci USA 2006;103:10224-9.
19. Choudhary C, Kumar C, Gnad F, et al. Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science 2009;325:834-40.
20. Kouzarides T. Chromatin modifications and their function. Cell 2007;128:693-705.
21. Yang XJ. Lysine acetylation and the bromodomain: a new partnership for signaling. Bioessays 2004;26:1076-87.
22. Shahbazian MD, Grunstein M. Functions of site-specific histone acetylation and deacetylation. Annu Rev Biochem 2007;76:75-100.
23. Yang H, Baur JA, Chen A, et al. Design and synthesis of compounds that extend yeast replicative lifespan. Aging Cell 2007;6:35-43.
24. Afshar G, Murnane JP. Characterization of a human gene with sequence homology to Saccharomyces cerevisiae SIR2. Gene 1999;234:161-8.
25. Jiang W, Wang S, Xiao M, et al. Acetylation regulates gluconeogenesis by promoting PEPCK1 degradation via recruiting the UBR5 ubiquitin ligase. Mol Cell 2011;43:33-44.
26. Rothgiesser KM, Erener S, Waibel S, et al. SIRT2 regulates NF-kappaB dependent gene expression through deacetylation of p65 Lys310. J Cell Sci 2010;123:4251-8.
27. Outeiro TF, Kontopoulos E, Altmann SM, et al. Sirtuin 2 inhibitors rescue alpha-synuclein-mediated toxicity in models of Parkinson's disease. Science 2007;317:516-9.
28. Luthi-Carter R, Taylor DM, Pallos J, et al. SIRT2 inhibition achieves neuroprotection by decreasing sterol biosynthesis. Proc Natl Acad Sci USA 2010;107:7927-32.
29. Wang RH, Sengupta K, Li C, et al. Impaired DNA damage response, genome instability, and tumorigenesis in SIRT1 mutant mice. Cancer Cell 2008;14:312-23.
30. Deng CX. SIRT1, is it a tumor promoter or tumor suppressor? Int J Biol Sci 2009;5:147-52.
31. Kim HS, Patel K, Muldoon-Jacobs K, et al. SIRT3 is a mitochondria-localized tumor suppressor required for maintenance of mitochondrial integrity and metabolism during stress. Cancer Cell 2010;17:41-52.
32. Tao R, Coleman MC, Pennington JD, et al. Sirt3-mediated deacetylation of evolutionarily conserved lysine 122 regulates MnSOD activity in response to stress. Mol Cell 2010;40:893-904.
33. Bell EL, Emerling BM, Ricoult SJ, et al. SirT3 suppresses hypoxia inducible factor 1 and tumor growth by inhibiting mitochondrial ROS production. Oncogene 2011;30:2986-96.
34. Finley LW, Carracedo A, Lee J, et al. SIRT3 opposes reprogramming of cancer cell metabolism through HIF1 destabilization. Cancer Cell 2011;19:416-28.
35. Jin YH, Kim YJ, Kim DW, et al. Sirt2 interacts with 14-3-3 beta/gamma and down-regulates the activity of p53. Biochem Biophys Res Commun 2008;368:690-5.
36. Peck B, Chen CY, Ho KK, et al. SIRT inhibitors induce cell death and p53 acetylation through targeting both SIRT1 and SIRT2. Mol Cancer Ther 2010;9:844-55.
37. Zhang Y, Au Q, Zhang M, et al. Identification of a small molecule SIRT2 inhibitor with selective tumor cytotoxicity. Biochem Biophys Res Commun 2009;386:729-33.
38. Heltweg B, Gatbonton T, Schuler AD, et al. Antitumor activity of a small-molecule inhibitor of human silent information regulator 2 enzymes. Cancer Res 2006;66:4368-77.
39. Ouaïssi M, Sielezneff I, Silvestre R, et al. High histone deacetylase 7 (HDAC7) expression is significantly associated with adenocarcinomas of the pancreas. Ann Surg Oncol 2008;15:2318-28.
40. Hiratsuka M, Inoue T, Toda T, et al. Proteomics-based identification of differentially expressed genes in human gliomas: down-regulation of SIRT2 gene. Biochem Biophys Res Commun 2003;309:558-66.
41. Guarente L. Sir2 links chromatin silencing, metabolism, and aging. Genes Dev 2000;14:1021-6.
42. Kyrylenko S, Kyrylenko O, Suuronen T, et al. Differential regulation of the Sir2 histone deacetylase gene family by inhibitors of class I and II histone deacetylases. Cellular and molecular life sciences. Cell Mol Life Sci 2003;60:1990-7.
43. Lombard DB, Chua KF, Mostoslavsky R, et al. DNA repair, genome stability, and aging. Cell 2005;120:497-512.
44. Mostoslavsky R, Chua KF, Lombard DB, et al. Genomic instability and aging-like phenotype in the absence of mammalian SIRT6. Cell 2006;124:315-29.
45. Kim HS, Vassilopoulos A, Wang RH, et al. SIRT2 maintains genome integrity and suppresses tumorigenesis through regulating APC/C activity. Cancer Cell 2011;20:487-99.
46. Rhodes DR, Yu J, Shanker K, et al. ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia 2004;6:1-6.
47. North BJ, Verdin E. Sirtuins: Sir2-related NADdependent protein deacetylases. Genome Biol 2004;5:224.
48. Dryden SC, Nahhas FA, Nowak JE, et al. Role for human SIRT2 NAD-dependent deacetylase activity in control of mitotic exit in the cell cycle. Mol Cell Biol 2003;23:3173-85.
49. Vaquero A, Sternglanz R, Reinberg D. NAD+-dependent deacetylation of H4 lysine 16 by class III HDACs. Oncogene 2007;26:5505-20.
50. Vaquero A, Scher MB, Lee DH, et al. SirT2 is a histone deacetylase with preference for histone H4 Lys 16 during mitosis. Genes Dev 2006;20:1256-61.
51. North BJ, Verdin E. Interphase nucleo-cytoplasmic shuttling and localization of SIRT2 during mitosis. PLoS ONE 2007;2:e784.
52. Inoue T, Hiratsuka M, Osaki M, et al. SIRT2, a tubulin deacetylase, acts to block the entry to chromosome condensation in response to mitotic stress. Oncogene 2007;26:945-7.
53. Inoue T, Nakayama Y, Yamada H, et al. SIRT2 downregulation confers resistance to microtubule inhibitors by prolonging chronic mitotic arrest. Cell Cycle 2009;8:1279-91.
54. Wang X, Zhou YX, Qiao W, et al. Overexpression of aurora kinase A in mouse mammary epithelium induces genetic instability preceding mammary tumor formation. Oncogene 2006;25:7148-58.
55. Saeki K, Iwasa Y. Optimal number of regulatory T cells. J Theor Biol 2010;263:210-8.
56. Garcia-Higuera I, Manchado E, Dubus P, et al. Genomic stability and tumour suppression by the APC/C cofactor Cdh1. Nat Cell Biol 2008;10:802-11.